Adamed Pharma Partners with the International Scientific Community

With a focus on international development and advancing innovation, Adamed Pharma is initiating scientific cooperation with Italian institutions, continuing to use its proven business model relying on partnerships with multiple scientific centres in Poland and globally. The company has now signed letters of intent with two leading Italian players: Fondazione Policlinico Universitario Agostino Gemelli and Università degli Studi di Milano.

Adamed Pharma signed letters of intent with teams from two high-profile Italian scientific organisations: Fondazione Policlinico Universitario Agostino Gemelli and Università degli Studi di Milano. In this way, the parties expressed their mutual intent to build a strong and lasting relationship in research, education and promotion of science. The future cooperation between Adamed Pharma and the institutions will involve the professional development of specialists, further advancement of medical knowledge, joint research projects and organisation of conferences. In the future, the initiative will have a positive effect on patients and the world of science in Poland as well as in Italy. The memorandums are part of Adamed Pharma’s broader international agenda. This year, the company has also signed a cooperation agreement with the Tashkent Medical Academy. Adamed has been present in Uzbekistan since 2020 and has funded eight grants for the best students.

Cooperation with the academic and scientific community is critical to the development of Adamed. Effective cooperation between the business and universities has long been identified as a prerequisite for innovation growth. Adamed has been engaged in cooperation with leading universities and research institutes in Poland and abroad for years. This model delivers many new solutions based on own patents and improvements to existing therapies. The knowledge and experience of the Adamed Pharma R&D team and scientists from partner institutions, combined with access to cutting-edge tools, contribute to the advancement of medicine and pharmacy.

In its development strategy, Adamed Pharma relies on innovation and internationalisation. The company has representative offices in nine countries, and its products are present on almost 80 markets. The development of the structures of Adamed Laboratorios in Spain and expansion of its product portfolio are currently Adamed Pharma’s largest project implemented in its foreign affiliates. The Spanish company has won the title of R&D leader in the pharmaceutical and biotechnology sectors in the Premios Madrid Futuro 2022 contest.